Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd.

BRAF/RAS-Mutant Solid Tumors (Melanoma, NSCLC, CRC)

Disease Overview

BRAF and NRAS mutations drive constitutive MAPK pathway signaling in solid tumors, most prominently melanoma but also NSCLC, CRC, and thyroid cancers. NRAS-mutant and BRAF non-V600/class II/III tumors lack effective targeted options because first-generation BRAF inhibitors (vemurafenib, dabrafenib) are V600-restricted and can paradoxically activate RAF in RAS-mutant settings.

Competitive Landscape

By late 2016 the BRAF V600 melanoma market was dominated by Roche's own Zelboraf (vemurafenib) and Cotellic (cobimetinib), Novartis's Tafinlar (dabrafenib) + Mekinist (trametinib), and Array's encorafenib + binimetinib (later Pfizer's Braftovi/Mektovi). All were V600-restricted and prone to paradoxical activation in NRAS- or class II/III-mutant disease, leaving a clear unmet need. Belvarafenib (HM95573 / GDC-5573) is a type II pan-RAF inhibitor that suppresses both BRAF monomers and BRAF/CRAF dimers, theoretically extending coverage to NRAS-mutant melanoma, BRAF non-V600 fusions, and KRAS-driven tumors. Genentech paired the asset with internal cobimetinib in a Phase 1b combo, generating a ~44% ORR in NRAS-mutant melanoma at the 2018 cut-off — the first credible signal in that biomarker. The deal therefore extends Roche's MAPK franchise beyond V600 melanoma and into RAS-driven indications, where the rest of the field is still struggling. Hanmi retained South Korean rights and a path back into oncology branded drugs after years of generics dependence.